Printer Friendly
The Free Library
4,482,753 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Neuro-Hitech Pharmaceuticals, Inc. Begins Trading under Symbol ''NHPI''; Private Placement of $4.35 Million Coincides with Reverse Merger.


NEW YORK -- Neuro-Hitech Pharmaceuticals, Inc., a drug development company engaged in the development and commercialization of Huperzine A (HupA Hupa: see Hoopa.) for a variety of degenerative de·gen·er·a·tive (d-jnr- neurological disorders, today announced its stock will begin trading under the symbol OTC BB: NHPI NHPI - N-hydroxyphthalimide
NHPI - National Health Provider Inventory
 today, February 2, 2006.

Neuro-Hitech completed a reverse merger with Northern Way Resources, Inc. The Company also sold 1,740,000 shares of common stock and warrants to purchase 435,000 shares of common stock exercisable at $5.00 per share for a purchase price of $25,000 per unit, each unit consisting of 10,000 shares and warrants for 2,500 shares. In exchange for the units, the Company received cash proceeds of $4.35 million.

Reuben Seltzer is the President and CEO of Neuro-Hitech as well as founding shareholder, and Alan Kestenbaum is Executive Vice President and a founding shareholder of Neuro-Hitech.

Through a collaboration with the Alzheimer's Disease Cooperative Study, the National Institutes of Health (NIH), and Georgetown University Medical Center, Neuro-Hitech has completed Phase I studies and is currently conducting a Phase II clinical trial for HupA, a cholinesterase
true cholinesterase  acetylcholinesterase.


cho·lin·es·ter·ase (kl-n
 inhibitor that may be effective in the treatment of Alzheimer's Disease. The company also believes that it may, in future, test the effectiveness of HupA in the treatment of Mild Cognitive Impairment.

Seltzer said, "We are excited by these events which we believe will give us the resources to complete our Phase II study and further our product development programs."

About Neuro-Hitech Pharmaceuticals, Inc.

Neuro-Hitech Pharmaceuticals, Inc., is a drug development company engaged in the development and commercialization of Huperzine A (HupA) for a variety of degenerative neurological disorders. Huperzine A is a plant alkaloid
ergot alkaloids  a group of chemically related alkaloids either derived from ergot or synthesized; some cause ergotism while others are medicinal.
vinca alkaloids  alkaloids produced by the common periwinkle plant (Vinca rosea); two, vincristine and vinblastine, are used as antineoplastic agents.
 derived from the Chinese club moss club moss, name generally used for the living species of the class Lycopodiopsida, a primitive subdivision of vascular plants. The Lycopodiopsida were a dominant plant group in the Carboniferous period, when they attained the size of trees, and contributed to the coal deposits then being formed. They are now considered relictual. plant.

This release contains forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 2, 2006
Words:373
Previous Article:Wisconsin, Illinois Welding Leaders Join Forces To Offer Integrated MIG Welding Systems.(Company Profile)
Next Article:Secretary Condoleezza Rice and Justice Anthony Kennedy among Featured Speakers at ASIL's 100th Annual Meeting.
Topics:



Related Articles
Hilstar Capital Corporation - Reverse Takeover of Kinesys Pharmaceutical Complete Conditional ASE Approval of Major Transaction.
HiTech Models Are Ready to Work US Fields.
Hispanic Insurer Set to Go Public In Reverse Merger.(Latino Health Care)(Brief Article)(Statistical Data Included)
Latino Health Care taking back route in change to Public Status. (Health Care).(Physician management company to go public)(Brief Article)
Quick Test 5 seeks investors through reverse merger. (Up Front).(Statistical Data Included)
Emerging from a shell spells major success for more firms.(SCORING L.A.'S PUBLIC COMPANIES)
Filling the GAP: doing "reverse mergers" into shell companies has become a major avenue for private companies seeking new capital, but established...
Reflect Scientific, Inc. Announces the Closing of Its Private Placement for the Merger of Cryomastor, Inc.
EPIX and Predix Pharmaceuticals Complete Merger.
Redpoint Bio Corporation and Robcor Properties, Inc. Complete Reverse Merger and Raise Approximately $20 Million in Private Placement Transaction.

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles